North America Gastrointestinal Drugs Market Analysis, Size, and Share by 2027

The North America gastrointestinal drugs market is expected to reach US$ 31,664.45 million by 2027 from US$ 21,292.53 million in 2019; it is estimated to grow at a CAGR of 5.2% from 2020 to 2027.

Gastrointestinal (GI) disorders are the medical conditions related to the digestive system that affect the colon, small and large intestine, and rectum. The disorders include constipation, irritable bowel, ulcerative colitis, and peptic ulcer diseases. These disorders are characterized by various symptoms such as pain, bloating, diarrhea, nausea, and vomiting. These disorders constitute a large proportion of outpatients and frequent hospital visits. A wide range of GI drugs is commercially available in the market for the treatment of various conditions. Additionally, rising investments in the development of biologics and the emergence of a biosimilar are expected to drive the growth of the market in the forecast period.

Growing prevalence of IBD can be ascribed to poor nutritional choices, including a high intake of ultra-processed foods and trans-fats. Western countries, such as the US, and Canada, are witnessing a high GI incidence rate due to increasing obesity in the adult population and less consumption of dietary fibers. As per the Centers for Disease Control and Prevention, in 2018, the number of visits to physician offices with the digestive system's diseases as the primary diagnosis was 22.4 million in the US. The incidence and prevalence of IBS have increased in the last few decades. As per the International Foundation for Gastrointestinal Disorders, IBS is the most common functional GI disorder with a prevalence rate of 10–15%. There are around 2.4–3.5 million physician visits for IBS annually in the US. As per the Crohn’s & Colitis Foundation of America, IBS affects approximately 1.6 million Americans. Around 70,000 new cases of IBD are diagnosed every year in the US. Apart from the US, other countries are also witnessing increasing burden of chronic digestive diseases due to the aging population and lifestyle factors such as rising obesity and heavy alcohol consumption. Thus, the factors mentioned above are driving the adoption of GI drugs during the forecast period.

North America has been witnessing a growing number of COVID-19 cases since its outbreak. Supply chain disruptions associated with this pandemic situation will ultimately affect the sales of products for short period. However, the OTC supply of gastrointestinal drug has been continuous in the pandemic as medical shops are allowed to open though everything is locked down. Several companies are cutting their clinical trial activities in response to the COVID-19 pandemic. However, in long run, market is expected to boost the demand of gastrointestinal drugs in the forecasted period. Therefore, growing demand for the constipation treatment in North America in long-term period is likely to boost the growth of the constipation treatment market.

Mexico Gastrointestinal Drugs Market, Revenue and Forecast to 2027 (US$ Mn)

NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SEGMENTATION

By Drug Class

• Acid Neutralizers
• Antidiarrheal and Laxatives
• Anti-Inflammatory Drugs
• Antiemetic and Antinauseants
• Biologics
• Others

By Route of Administration

• Oral
• Parenteral

By Application

• Inflammatory Ulcerative Colitis
• Crohn's Disease
• Irritable Bowel Syndrome
• Gastroenteritis
• Celiac Disease
• Others

By Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

By Country

• US
• Canada
• Mexico

Company Profiles

• Johnson and Johnson Services, Inc.
• Bausch Health
• AbbVie Inc.
• LEXICON PHARMACEUTICALS, INC
• Takeda Pharmaceutical Company Limited

North America Gastrointestinal Drugs Report Scope